The 340B drug pricing program is a cornerstone for community-based health systems, allowing them to stretch limited resources and provide essential care to uninsured and underinsured patients. However, the program faces mounting challenges that hospital leaders cannot afford to ignore.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
